Milestone payments are becoming an increasingly familiar aspect of many biotech deals, as buyers try to mitigate the risks inherent with big purchases. Take Celgene’s $2.9 billion buyout of Abraxis; the biotech giant set aside $650 million in milestone payments if Abraxis’ key drug Abraxane hit certain goals. “These structures are a great way for [...]
Oncologics, lipid regulators, respiratory agents, antidiabetics and anti-ulcerants are the five largest drug classes by sales. But annual sales are only half the story. Which drug classes are booming, and which have plateaued–or even dropped? IMS Health has released top-line industry data revealing the 15 largest drug classes, and we’ve crunched the numbers to take a closer [...]
Eli Lilly (NYSE: LLY) is looking to its pipeline to fill the gaps left by a number of high-profile drugs coming off patent. In October 2011, blockbuster Zyprexa will fall to generic competition; additionally, about three-quarters of Lilly’s current revenue comes from eight drugs that will lose patent protection between now and 2017. ”We have the challenge [...]
In the quest for a cancer vaccine, Merck KGaA is again stepping into the ring. Vaximm Holding AG, the company’s joint venture with a Switzerland’s BB Biotech Ventures III, will start testing a therapeutic cancer vaccine in patients next year. The vaccine, VXM01, harnesses the body’s immune system to fight cancer by using T-cells to close off [...]
The molecular machinery that switches on a gene known to cause breast cancer to spread and invade other organs has been identified by an international team led by scientists at The University of Texas M. D. Anderson Cancer Center. The paper was published in Nature Cell Biology’s advanced online publication.
A heart patient’s own skin cells soon could be used to repair damaged cardiac tissue thanks to pioneering stem cell research of the University of Houston’s newest biomedical scientist, Robert Schwartz. His new technique for reprogramming human skin cells puts him at the forefront of a revolution in medicine that could one day lead to [...]
Monash University biomedical scientists have identified a new way to treat castrate resistant cells in prostate cancer sufferers — the most common cancer in Australian men. For more than 60 years the main way to treat men with prostate cancer has involved removing the hormones that fuel growth of the cancer cells. Although initially effective [...]
Knowing the stage of a patient’s melanoma is important when choosing the best course of treatment. When the cancer has progressed to the lymph nodes, a more aggressive treatment is needed. Examining an entire lymph node for cancer takes much effort and time. Now, a new technique might help make the process more efficient.
The FDA completed reviewing data that appeared to indicate an increase in cancer rates and cancer deaths stemming from the use of Zetia and Vyotrin. The FDA concluded that it was unlikely that either of these drugs boost cancer rates. The FDA also left the door open for future study by stating that the links [...]
New research studies conducted on a large cross section of prostate cancer patients has revealed that when it comes to the chances of recurrence after surgery, both blacks and whites are equally susceptible. In conclusion, being overweight is equally harmful to both blacks and whites. Read more about Commercial Insight: Antihormonal Cancer Therapies
You are currently browsing the weblog archives for 'Prostate Cancer' tag.
Longer entries are truncated. Click the headline of an entry to read it in its entirety.
Biotech Trading Signals Pharma News Biotech News